BRPI0719393B8 - composição farmacêutica - Google Patents

composição farmacêutica

Info

Publication number
BRPI0719393B8
BRPI0719393B8 BRPI0719393A BRPI0719393A BRPI0719393B8 BR PI0719393 B8 BRPI0719393 B8 BR PI0719393B8 BR PI0719393 A BRPI0719393 A BR PI0719393A BR PI0719393 A BRPI0719393 A BR PI0719393A BR PI0719393 B8 BRPI0719393 B8 BR PI0719393B8
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
disclosed
general formula
compound represented
composition containing
Prior art date
Application number
BRPI0719393A
Other languages
English (en)
Inventor
Maeda Kazuko
Watanabe Tomoyuki
Original Assignee
Daiichi Sankyo Co Ltd
Ube Industries
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd, Ube Industries filed Critical Daiichi Sankyo Co Ltd
Publication of BRPI0719393A2 publication Critical patent/BRPI0719393A2/pt
Publication of BRPI0719393B1 publication Critical patent/BRPI0719393B1/pt
Publication of BRPI0719393B8 publication Critical patent/BRPI0719393B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

composição farmacêutica. é revelada uma composição farmacêutica contendo um composto representado pela fórmula geral (i) abaixo ou um sal farmacologicamente aceitável do mesmo, enquanto que tem dissolubilidade melhora especificamente é revelada uma composição farmacêutica contendo (a) um composto representado pela fórmula geral (i) abaixo ou um sal farmacologicamente do mesmo, e (b) uma hidróxipropil-celulose pouco substituída.
BRPI0719393A 2006-12-07 2007-12-06 composição farmacêutica BRPI0719393B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2006-330375 2006-12-07
JP2006330375 2006-12-07
PCT/JP2007/073552 WO2008072535A1 (ja) 2006-12-07 2007-12-06 低置換度ヒドロキシプロピルセルロースを含有する医薬組成物

Publications (3)

Publication Number Publication Date
BRPI0719393A2 BRPI0719393A2 (pt) 2015-03-31
BRPI0719393B1 BRPI0719393B1 (pt) 2020-11-10
BRPI0719393B8 true BRPI0719393B8 (pt) 2021-05-25

Family

ID=39511555

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0719393A BRPI0719393B8 (pt) 2006-12-07 2007-12-06 composição farmacêutica

Country Status (9)

Country Link
US (1) US9034860B2 (pt)
EP (1) EP2100610A4 (pt)
JP (1) JP5274261B2 (pt)
KR (1) KR101506043B1 (pt)
CN (1) CN101594865A (pt)
BR (1) BRPI0719393B8 (pt)
CA (1) CA2671979C (pt)
TW (1) TWI482641B (pt)
WO (1) WO2008072535A1 (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7736310B2 (en) 2006-01-30 2010-06-15 Abbott Diabetes Care Inc. On-body medical device securement
US8346335B2 (en) 2008-03-28 2013-01-01 Abbott Diabetes Care Inc. Analyte sensor calibration management
US9339217B2 (en) 2011-11-25 2016-05-17 Abbott Diabetes Care Inc. Analyte monitoring system and methods of use
JPWO2008069262A1 (ja) * 2006-12-07 2010-03-25 第一三共株式会社 安定性が改善されたフィルムコーティング製剤
WO2008072532A1 (ja) * 2006-12-07 2008-06-19 Daiichi Sankyo Company, Limited 貯蔵安定性が改善された医薬組成物
JP5289975B2 (ja) * 2006-12-07 2013-09-11 第一三共株式会社 マンニトール又は乳糖を含有する固形製剤
US8160900B2 (en) 2007-06-29 2012-04-17 Abbott Diabetes Care Inc. Analyte monitoring and management device and method to analyze the frequency of user interaction with the device
EP2257556A1 (en) 2008-02-06 2010-12-08 Helm AG Prasugrel salts with improved properties
US8924159B2 (en) 2008-05-30 2014-12-30 Abbott Diabetes Care Inc. Method and apparatus for providing glycemic control
US8591410B2 (en) 2008-05-30 2013-11-26 Abbott Diabetes Care Inc. Method and apparatus for providing glycemic control
WO2010121084A1 (en) 2009-04-15 2010-10-21 Abbott Diabetes Care Inc. Analyte monitoring system having an alert
EP2425209A4 (en) 2009-04-29 2013-01-09 Abbott Diabetes Care Inc METHOD AND SYSTEM FOR REAL-TIME CALIBRATION OF AN ANALYTICAL SENSOR WITH RETROACTIVE FILLING
DE102009036646A1 (de) * 2009-08-07 2011-02-10 Ratiopharm Gmbh Prasugrel in nicht-kristalliner Form und pharmazeutische Zusammensetzung davon
WO2011026053A1 (en) 2009-08-31 2011-03-03 Abbott Diabetes Care Inc. Displays for a medical device
EP2360159A1 (de) 2010-02-11 2011-08-24 Ratiopharm GmbH Prasugrel in mikronisierter, kristalliner Form und pharmazeutische Zusammensetzung davon
US10136845B2 (en) 2011-02-28 2018-11-27 Abbott Diabetes Care Inc. Devices, systems, and methods associated with analyte monitoring devices and devices incorporating the same
US9317656B2 (en) 2011-11-23 2016-04-19 Abbott Diabetes Care Inc. Compatibility mechanisms for devices in a continuous analyte monitoring system and methods thereof
CZ2011872A3 (cs) 2011-12-22 2013-07-03 Zentiva, K.S. Farmaceutická formulace prasugrelu hydrobromidu
JP6122098B2 (ja) * 2012-03-30 2017-04-26 デウン ファーマシューティカル カンパニー リミテッド オルメサルタンメドキソミルとロスバスタチンまたはその塩とを含む医薬組成物
US8603537B2 (en) 2012-04-02 2013-12-10 Egis Pharmaceuticals Plc Prasugrel containing quickly released stable oral pharmaceutical compositions
WO2014052136A1 (en) 2012-09-26 2014-04-03 Abbott Diabetes Care Inc. Method and apparatus for improving lag correction during in vivo measurement of analyte concentration with analyte concentration variability and range data
EP2722037A1 (en) * 2012-10-19 2014-04-23 Sanovel Ilac Sanayi ve Ticaret A.S. Prasugrel formulations
WO2014060560A1 (en) * 2012-10-19 2014-04-24 Sanovel Ilac Sanayi Ve Ticaret A.S. Solid oral formulations of prasugrel
WO2016122421A1 (en) * 2015-01-29 2016-08-04 Pharmactive Ilaç Sanayi Ve Ticaret A.Ş. Stable pharmaceutical compositions containing prasugrel base
KR101960357B1 (ko) 2016-12-26 2019-03-20 씨제이헬스케어 주식회사 벤즈이미다졸 유도체를 포함하는 신규한 제제

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US147951A (en) * 1874-02-24 Improvement in car-wheels
US1656930A (en) * 1924-01-09 1928-01-24 American Steel Foundries Method for forging brake-beam fulcrums
JPS5942325A (ja) 1982-09-03 1984-03-08 Dai Ichi Seiyaku Co Ltd コ−テイング用組成物及びコ−テイング製剤
US5015480A (en) 1987-11-25 1991-05-14 Eli Lilly And Company Film coating formulations
ATE72118T1 (de) 1987-11-30 1992-02-15 Gist Brocades Nv Pharmazeutische zusammensetzung und verfahren zu ihrer herstellung.
US5211958A (en) 1987-11-30 1993-05-18 Gist-Brocades, N.V. Pharmaceutical composition and process for its preparation
JPH01175936A (ja) 1987-12-28 1989-07-12 Kyorin Pharmaceut Co Ltd ６．８−ジフルオロ−１−（２−フルオロエチル）−１，４−ジヒドロ−７−（４−メチル−１−ピペラジニル）−４−オキソ−３−キノリンカルボン酸を有効成分とする錠剤
JPH02240024A (ja) 1989-03-13 1990-09-25 Ss Pharmaceut Co Ltd 活性型ビタミンｄ↓３類製剤用組成物
US4931286A (en) 1989-04-19 1990-06-05 Aqualon Company High gloss cellulose tablet coating
FI101150B (fi) 1991-09-09 1998-04-30 Sankyo Co Menetelmä lääkeaineina käyttökelpoisten tetrahydrotienopyridiinin johd annaisten valmistamiseksi
ZA937382B (en) 1992-10-06 1994-04-29 Warner Lambert Co Novel composition for peroral therapy of cognitionimpairment and a process therefor
JPH0770506A (ja) 1993-09-07 1995-03-14 Morishita Roussel Kk フイルムコーティング組成物およびそれを用いた固形製剤
JP3583166B2 (ja) 1994-06-27 2004-10-27 興和株式会社 損傷皮膚修復用粉末製剤
GB9414045D0 (en) 1994-07-12 1994-08-31 Berwind Pharma Service Moisture barrier film coating composition, method, and coated form
JP3274573B2 (ja) 1994-08-25 2002-04-15 興和株式会社 フィルムコーティング組成物およびそれを用いた固形製剤
JPH092953A (ja) 1995-06-16 1997-01-07 Chugai Pharmaceut Co Ltd バルフロキサシン製剤
JPH09208458A (ja) 1996-02-02 1997-08-12 Ss Pharmaceut Co Ltd 不快な味がマスキングされた製剤
ATE287218T1 (de) 1996-02-29 2005-02-15 Fujisawa Pharmaceutical Co Schnellzerfallendes granulate von einem synthetischen süssstoff enthaltend kieselsäure und/oder siliciumdioxid
JPH10310586A (ja) 1996-06-26 1998-11-24 Sankyo Co Ltd ヒドロピリジン類の新規医薬用途
KR100343062B1 (ko) * 1996-11-15 2002-07-02 에가시라 구니오 정제 조성물
EP1203580A4 (en) 1999-06-18 2004-06-30 Takeda Chemical Industries Ltd SOLID PREPARATIONS WITH FAST DISINTEGRATION
EP1133984B1 (en) * 2000-03-17 2005-05-11 Shin-Etsu Chemical Co., Ltd. Solid preparation containing low-substituted hydroxypropyl cellulose and production process thereof
CA2342121C (fr) 2000-03-29 2010-05-25 Roquette Freres Mannitol pulverulent et son procede de preparation
FR2807034B1 (fr) 2000-03-29 2002-06-14 Roquette Freres Mannitol pulverulent et son procede de fabrication
JP4001199B2 (ja) * 2000-07-06 2007-10-31 第一三共株式会社 ヒドロピリジン誘導体酸付加塩
HU230762B1 (hu) 2000-07-06 2018-03-28 Daiichi Sankyo Company, Limited Hidropiridin-származékok maleát addíciós sója
EP1175899B1 (fr) 2000-07-27 2007-08-29 Roquette FrÀ¨res Granules à base d'amidon et de lactose
ES2311498T3 (es) 2000-12-25 2009-02-16 Daiichi Sankyo Company, Limited Composiciones medicinales que contienen aspirina.
JP4874482B2 (ja) 2000-12-25 2012-02-15 第一三共株式会社 アスピリンを含有する医薬組成物
JP3939601B2 (ja) 2001-06-20 2007-07-04 株式会社アクティバスファーマ キノリノン誘導体医薬組成物及びその製造方法
KR100908418B1 (ko) 2001-06-20 2009-07-21 액티버스 파마 컴퍼니 리미티드 퀴놀리논 유도체 의약 조성물 및 그의 제조 방법
JP2003160500A (ja) 2001-11-21 2003-06-03 Showa Yakuhin Kako Kk ポピドンヨード含有組成物
JP4029974B2 (ja) 2001-12-21 2008-01-09 第一三共株式会社 ヒドロピリジン誘導体酸付加塩を含有する医薬
IL166312A0 (en) 2002-07-18 2006-01-15 Sankyo Co A pharmaceutical composition containing an adp receptor antagonist and an acat inhibitor
US20050192245A1 (en) 2002-07-18 2005-09-01 Sankyo Company, Limited Medicinal composition for treating arteriosclerosis
JP2004051639A (ja) 2002-07-18 2004-02-19 Sankyo Co Ltd 動脈硬化症治療のための医薬組成物
CA2522112A1 (en) 2003-04-16 2004-10-28 Kyorin Pharmaceutical Co., Ltd. Solid preparation for oral use
EP1660183A2 (en) 2003-05-05 2006-05-31 Eli Lilly and Company Treating cardiovascular diseases with a compound of formula 1 (cs 747 - prasugrel; rn 150322-43-4)
WO2005013964A1 (ja) 2003-08-08 2005-02-17 Ajinomoto Co., Inc. ナテグリニド含有製剤
JP5248733B2 (ja) 2003-11-28 2013-07-31 エスエス製薬株式会社 揮散防止型固形製剤およびその製造方法
JP2006206612A (ja) 2004-05-27 2006-08-10 Ono Pharmaceut Co Ltd 固形製剤用組成物
EP1656930A1 (en) 2004-11-10 2006-05-17 Basilea Pharmaceutica AG Stabilized freeze-dried formulation for cephalosporin derivatives
TWI318571B (en) 2005-06-10 2009-12-21 Lilly Co Eli Formulation of a thienopyridine platelet aggregation inhibitor
EP1893205A4 (en) 2005-06-17 2010-06-30 Lilly Co Eli DOSAGE FOR PRASUGREL
WO2007020935A1 (ja) 2005-08-17 2007-02-22 Ono Pharmaceutical Co., Ltd. Ｐ２ｙ１２受容体および／またはｐ２ｙ１４受容体ブロッカーを含有してなる疼痛治療剤
TWI405591B (zh) 2006-12-07 2013-08-21 Daiichi Sankyo Co Ltd 固形製劑之製造方法
WO2008072532A1 (ja) 2006-12-07 2008-06-19 Daiichi Sankyo Company, Limited 貯蔵安定性が改善された医薬組成物
JP5289975B2 (ja) 2006-12-07 2013-09-11 第一三共株式会社 マンニトール又は乳糖を含有する固形製剤
JPWO2008069262A1 (ja) 2006-12-07 2010-03-25 第一三共株式会社 安定性が改善されたフィルムコーティング製剤
US20110020814A1 (en) * 2009-06-05 2011-01-27 Ipierian, Inc. Methods and compositions for selection of stem cells

Also Published As

Publication number Publication date
TW200833370A (en) 2008-08-16
TWI482641B (zh) 2015-05-01
CA2671979A1 (en) 2008-06-19
WO2008072535A1 (ja) 2008-06-19
EP2100610A4 (en) 2009-12-02
KR20090100339A (ko) 2009-09-23
KR101506043B1 (ko) 2015-03-25
CN101594865A (zh) 2009-12-02
BRPI0719393B1 (pt) 2020-11-10
JP5274261B2 (ja) 2013-08-28
US9034860B2 (en) 2015-05-19
BRPI0719393A2 (pt) 2015-03-31
CA2671979C (en) 2014-02-04
US20100093786A1 (en) 2010-04-15
EP2100610A1 (en) 2009-09-16
JPWO2008072535A1 (ja) 2010-03-25

Similar Documents

Publication Publication Date Title
BRPI0719393B8 (pt) composição farmacêutica
ME01992B (me) Jedinjenje diarilhidantoina
TW200744588A (en) Pharmaceutical composition for external use
TW200728307A (en) Novel spirochromanone derivatives
CY1114892T1 (el) Φαρμακευτικη συνθεση ενος ισχυρου αναστολεα του hcv για απο του στοματος χορηγηση
MX2007005694A (es) Nuevos derivados de betulina, preparacion y uso de los mismos.
EA200970585A1 (ru) Бензамидные производные как агонисты ер-рецепторов
TN2009000180A1 (en) NOVEL 1,4-BENZOTHIEPIN-l,1-DIOXIDE DERIVATIVES WHICH ARE SUBSTITUTED WITH BENZYL GROUPS, METHOD FOR PRODUCING DRUGS CONTAINING SAID COMPOUNDS AND USE THEREOF
BRPI0621386B8 (pt) composição farmacêutica para o uso externo
CY1113395T1 (el) Σταθερη φαρμακευτικη συνθεση που περιεχει πυριμιδινη-σουλφαμιδη
BRPI0719395C1 (pt) tablete revestido de filme
UA94606C2 (ru) Производные тиоксантина, композиция, которая их содержит, и их применение в терапии
PT2310356E (pt) Derivados de adamantildiamida e a sua utilização
RS52700B (en) SUBSTITUTED OXINDOL DERIVATIVE AND ITS USE AS A VASOPRESIN RECEPTOR LIGAND
ATE495176T1 (de) Spiroindolinon-derivate
BR112016011755A2 (pt) derivado de ureia ou sal farmacologicamente aceitável do mesmo
MY151295A (en) Pyrimidyl indoline compound
AR062211A1 (es) Derivados de 6-carboxi-normorfinano. composiciones farmaceuticas
NI201200168A (es) Formulaciones farmacéuticas
TW200637817A (en) 5-aminoindole derivatives
BRPI0806789B8 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo
ATE449776T1 (de) Pyrroloä2,3-cüpyridinderivate
UA95095C2 (en) 11 beta-hydroxyandrosta-1,4-diene-3-ones
UA97369C2 (ru) Противоопухолевые соединения дигидропиран-2-она и фармацевтическая композиция на их основе
MX2009003169A (es) Derivados de sulfonamida.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 10/11/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 06/12/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B25D Requested change of name of applicant approved

Owner name: DAIICHI SANKYO COMPANY LIMITED (JP) ; UBE CORPORATION (JP)